LIfT BioSciences
Lift Biosciences is a rapidly emerging biotech company bringing to market a first-in-class allogeneic innate cell therapy. Learn more
Launch date
Employees
Market cap
-
Enterprise valuation
€12m (Public information from Jan 2020)
Company register number 09277638
London England (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | £310k | Seed | |
£17.6k | Grant | ||
£2.0m | Seed | ||
| N/A | £540k Valuation: £10.0m | Seed | |
* | N/A | N/A | - |
* | £1.0m | Grant | |
| Total Funding | €4.6m | ||
Related Content
Recent News about LIfT BioSciences
EditMore about LIfT BioSciences
EditLIfT Biosciences® has a breakthrough allogeneic innate immuno-cell therapy platform called Neutrophil Only Leukocyte Infusion Therapy (N-LIfT®) that allows us to produce different types of Immunomodulatory Alpha Neutrophils (IMAN®s) at scale from iPSCs for a wide range of different purposes as a mono or combo.
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.